Corcept Therapeutics Newswire (Page 4)

Corcept Therapeutics Newswire (Page 4)

Comprehensive Real-Time News Feed for Corcept Therapeutics. (Page 4)

Results 61 - 80 of 794 in Corcept Therapeutics

  1. Corcept Therapeutics (CORT) Stock Rating Lowered by BidaskClubRead the original story w/Photo

    Mar 31, 2018 | Daily Political

    Other research analysts also recently issued research reports about the stock. Piper Jaffray set a $30.00 target price on shares of Corcept Therapeutics and gave the company a "buy" rating in a research report on Monday, February 5th.

    Comment?

  2. Corcept Therapeutics (CORT) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Mar 30, 2018 | AmericanBankingNews.com

    ... A number of other equities analysts have also recently commented on the stock. BidaskClub cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, December 20th. Piper Jaffray set a $30.00 price ...

    Comment?

  3. Corcept Therapeutics Incorporated (CORT) Stake Increased by Teachers Advisors LLCRead the original story w/Photo

    Mar 30, 2018 | AmericanBankingNews.com

    Teachers Advisors LLC lifted its holdings in Corcept Therapeutics Incorporated by 9.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 952,585 shares of the biotechnology company's stock after buying an additional 81,697 shares during the period.

    Comment?

  4. Rainier Investment Management Has Trimmed Its Quanta Svcs (PWR) Stake; Cubic Has 1.13 SentimentRead the original story w/Photo

    Mar 30, 2018 | Hill Country Times

    ... Quanta Services, Inc. for the previous quarter, Wall Street now forecasts -35.00% negative EPS growth. Corcept Therapeutics (CORT) Moves On B. Riley Initiation with $30 Target; Verona Pharma Plc - American Depositary Share (VRNA) SI Decreased By ...

    Comment?

  5. Corcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by BrokeragesRead the original story w/Photo

    Mar 28, 2018 | AmericanBankingNews.com

    Shares of Corcept Therapeutics Incorporated have been given an average recommendation of "Buy" by the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

    Comment?

  6. Corcept Therapeutics (CORT) Stock Rating Upgraded by BidaskClubRead the original story w/Photo

    Mar 26, 2018 | AmericanBankingNews.com

    Other research analysts also recently issued reports about the company. Piper Jaffray set a $30.00 price objective on Corcept Therapeutics and gave the company a "buy" rating in a research note on Tuesday, October 31st.

    Comment?

  7. Corcept Therapeutics (CORT) PT Set at $30.00 by Piper Jaffray CompaniesRead the original story w/Photo

    Mar 25, 2018 | AmericanBankingNews.com

    ... recently issued research reports about the company. Stifel Nicolaus dropped their price objective on Corcept Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Monday, February 5th. BidaskClub downgraded Corcept ...

    Comment?

  8. UBS Asset Management Americas Inc. Has $1.03 Million Stake in Corcept ...Read the original story w/Photo

    Mar 25, 2018 | AmericanBankingNews.com

    UBS Asset Management Americas Inc. grew its holdings in shares of Corcept Therapeutics Incorporated by 44.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fund owned 57,249 shares of the biotechnology company's stock after buying an additional 17,566 shares during the quarter.

    Comment?

  9. $56.54 Million in Sales Expected for Corcept Therapeutics Incorporated (CORT) This QuarterRead the original story w/Photo

    Mar 24, 2018 | The Breeze

    Wall Street brokerages predict that Corcept Therapeutics Incorporated will report $56.54 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Corcept Therapeutics' earnings, with the highest sales estimate coming in at $58.08 million and the lowest estimate coming in at $55.00 million.

    Comment?

  10. Corcept Therapeutics (CORT) Trading Up 5.2%Read the original story w/Photo

    Mar 12, 2018 | IntersportsWire

    Corcept Therapeutics Incorporated shares were up 5.2% during mid-day trading on Monday . The company traded as high as $17.79 and last traded at $17.40.

    Comment?

  11. Corcept Therapeutics (CORT) Now Covered by Analysts at B. RileyRead the original story w/Photo

    Mar 12, 2018 | Daily Political

    ... stock. CORT has been the subject of a number of other research reports. BidaskClub cut shares of Corcept Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, February 7th. Stifel Nicolaus lowered their price ...

    Comment?

  12. Short Interest in Corcept Therapeutics Incorporated (CORT) Rises By 11.5%Read the original story w/Photo

    Mar 10, 2018 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 16,292,805 shares, a growth of 11.5% from the February 15th total of 14,616,919 shares.

    Comment?

  13. Robert S. Fishman Sells 8,000 Shares of Corcept Therapeutics Incorporated (CORT) StockRead the original story w/Photo

    Mar 10, 2018 | The Breeze

    Corcept Therapeutics Incorporated insider Robert S. Fishman sold 8,000 shares of the company's stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $15.67, for a total value of $125,360.00.

    Comment?

  14. Best Health Care Website to be Named by Web Marketing Association in 22nd Annual WebAward CompetitionRead the original story w/Photo

    Mar 9, 2018 | PR.com

    ... - 2016 IPG Marketing Team for IPG.com Website Re-Design - 2015 Ha Design Studio for Trainer Rx - 2014 - Corcept Therapeutics & Heartbeat Ideas for Cushing's Connection - 2013 Incubate for Shire: HealTogether - 2012 - Cyber-Duck Ltd for London ...

    Comment?

  15. Corcept Therapeutics Incorporated (CORT) Insider Robert S. Fishman Sells 8,000 SharesRead the original story w/Photo

    Mar 8, 2018 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated insider Robert S. Fishman sold 8,000 shares of the firm's stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $15.67, for a total value of $125,360.00.

    Comment?

  16. Corcept Therapeutics (CORT) Now Covered by Analysts at B. RileyRead the original story w/Photo

    Mar 8, 2018 | AmericanBankingNews.com

    ... of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Corcept ...

    Comment?

  17. Renee D. Gala Acquires 10,000 Shares of Corcept Therapeutics Incorporated (CORT) StockRead the original story w/Photo

    Mar 7, 2018 | AmericanBankingNews.com

    Corcept Therapeutics Incorporated Director Renee D. Gala bought 10,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, March 7th. The shares were acquired at an average cost of $15.51 per share, with a total value of $155,100.00.

    Comment?

  18. Corcept Therapeutics Incorporated (CORT) Holdings Lifted by Schwab Charles Investment Management Inc.Read the original story w/Photo

    Mar 7, 2018 | Daily Political

    Schwab Charles Investment Management Inc. grew its holdings in shares of Corcept Therapeutics Incorporated by 16.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 480,924 shares of the biotechnology company's stock after purchasing an additional 66,749 shares during the quarter.

    Comment?

  19. Bogle Investment Management L P de Has $12.75 Million Holdings in...Read the original story w/Photo

    Mar 2, 2018 | AmericanBankingNews.com

    Bogle Investment Management L P DE lifted its position in shares of Corcept Therapeutics Incorporated by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission . The institutional investor owned 705,941 shares of the biotechnology company's stock after acquiring an additional 17,009 shares during the quarter.

    Comment?

  20. Corcept Therapeutics (CORT) Stake Held by Timpani Capital Management...Read the original story

    Feb 24, 2018 | Hill Country Times

    Corcept Therapeutics Stake Held by Timpani Capital Management Llc; As 3 Shares Rose, Shareholder Concourse Capital Management Has Cut Its Holding by $374,400 Concourse Capital Management Llc decreased its stake in 3 by 45.47% based on its latest 2017Q3 regulatory filing with the SEC. Concourse Capital Management Llc sold 28,800 shares as the company's stock rose 26.87% with the market.

    Comment?